Hemogenyx Pharmaceuticals director to resign
Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds
Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall
Global M&A By the Numbers: Q1 2022
Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes
Hemogenyx Pharmaceuticals Plc said Robin Campbell would resign as a nonexecutive director, effective Jan. 5, 2019.
London-based Hemogenyx Pharmaceuticals is a preclinical-stage biotechnology company that focuses on the discovery, development and commercialization of novel therapies and treatments for blood diseases.